Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 5 of 3794 for:    NOW

Nutrigenomics, Overweight/Obesity and Weight Management Trial (NOW Trial) (NOW)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by Western University, Canada
Sponsor:
Collaborators:
Nutrigenomix Inc.
East Elgin Family Health Team
Canadian Transplant Association
Information provided by (Responsible Party):
Western University, Canada
ClinicalTrials.gov Identifier:
NCT03015012
First received: January 5, 2017
Last updated: April 25, 2017
Last verified: January 2017
  Purpose

The investigators hypothesize that compared to the provision of population-based dietary advice, providing DNA-based dietary advice via personalized nutrigenomics testing (PNT) to 2 distinct patient populations (patients at risk for type 2 diabetes and transplant recipients) will motivate them to adopt healthier dietary habits, lead to greater fat loss, increased percent lean mass and therefore improve health and quality of life outcomes for both patient populations. The second hypothesis is that dietary strategies related to the intake of one or more dietary components of interest will mitigate post-transplant weight gain associated with three SNPs of interest.

This is a randomized clinical intervention trial involving a total of six groups of patients (n = 450). The two main patient groups include overweight or obese stable transplant recipients and overweight or obese patients who are at risk for type 2 diabetes. Within these two main groups, there will be three sub-groups. Patients in each of the two main groups will either self-select to be in the control group or will be randomized to receive either PNT or standard nutrition intervention (SNI). Baseline data will be conducted consisting of a 24-hour recall, food frequency questionnaire and 3-day food records using a validated multiple pass method. Bioelectrical Impedance Analysis (BIA) will be conducted to assess body composition and to derive percent body fat and lean mass. Weight and height will be measured using a weigh scale and stadiometer. Those patients randomized to the PNT group will be instructed on a tailored nutrition care plan and physical activity recommendations based on their individual nutrigenomics profile. At the same time, the SNI group will be instructed on general nutrition and physical activity recommendations for weight loss, which include the use of dietary strategies from the standard tool ('Just the Basics') used by registered dietitians for transplant patients and patients at risk for type 2 diabetes. Monthly email reminders or phone calls (depending on patient's preference) will be sent to all participants as a reminder of their nutrition plan. 3 months, 6 months and 12 months after baseline data collection and individual nutrition interventions, baseline data will be repeated. After the study is complete, participants in the SNI group and control group will be offered a nutrigenomics report and consultation with a registered dietitian.

A paired t-test will be used to assess within group change from baseline to each follow-up time point for: BMI, body fat, lean mass, and dietary intake. A repeated measures ANOVA will be used to test between group differences from baseline to each follow-up time point for: BMI, body fat, lean mass, and dietary intake. If significant mean differences are detected, a Tukey's post hoc test will be used to compare differences by group. Statistical significance will be determined by P < 0.05. General linear regression models will be used to assess interactions between each genotype of interest and each dietary component of interest on BMI and body composition from baseline to each follow-up time point.


Condition Intervention
Transplant-Related Disorder
Overweight and Obesity
Genetic: Personalized Nutrigenomics Testing (PNT)
Other: Standard Nutrition Intervention (SNI)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Prevention
Official Title: Using Personalized Nutrigenomics Testing to Mitigate Overweight/Obesity Risk in Two Distinct Patient Populations: A Multicentre Randomized Clinical Intervention Trial

Further study details as provided by Western University, Canada:

Primary Outcome Measures:
  • Change in Body Composition [ Time Frame: 3 months, 6 months, 12 months ]
    Change in body composition will be assessed using BIA which will provide information on fat mass, lean mass, and water weight

  • Change in BMI [ Time Frame: 3 months, 6 months, 12 months ]
    Change in BMI will be assessed using height and weight data


Secondary Outcome Measures:
  • Change in Dietary Intake [ Time Frame: 3 months, 6 months, 12 months ]
    Change in dietary intake will be assessed using pre- and post- dietary data collected using 24-hour recalls and 3-day food records.


Other Outcome Measures:
  • Nutrigenomics Interactions [ Time Frame: 3 months, 6 months, 12 months ]
    Nutrigenomics (nutrition-genetic) interactions between ACE gene variants at rs4343, FTO gene variants at rs1558902 (in strong linkage disequilibrium with rs9939609) and MC4R (rs571312) to mitigate risk of post-transplant weight gain will be assessed for transplant recipients in the PNT group.


Estimated Enrollment: 450
Actual Study Start Date: April 3, 2017
Estimated Study Completion Date: February 2020
Estimated Primary Completion Date: February 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Standard Nutrition Intervention (SNI)
Participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team (those at risk for type 2 diabetes) will complete the standard GLB Program. Each participant will receive a monthly follow-up email or phone call reviewing their nutrition plan, until 12 months after baseline data collection.
Other: Standard Nutrition Intervention (SNI)
Participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team (those at risk for type 2 diabetes) will complete the standard GLB Program. Each participant will receive a monthly follow-up email or phone call reviewing their nutrition plan, until 12 months after baseline data collection.
Experimental: Personalized Nutrigenomics Testing (PNT)
Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team (those at risk for type 2 diabetes) will complete the GLB Program, but will be given personalized nutrition advice based on the results of their nutrigenomics test. Each participant will receive a monthly follow-up email or phone call reviewing their nutrition plan, until 12 months after baseline data collection.
Genetic: Personalized Nutrigenomics Testing (PNT)
Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team (those at risk for type 2 diabetes) will complete the GLB Program, but will be given personalized nutrition advice based on the results of their nutrigenomics test. Each participant will receive a monthly follow-up email or phone call reviewing their nutrition plan, until 12 months after baseline data collection.
No Intervention: Control Group
Participants will be instructed to continue consuming their usual diet and following their usual physical activity regime.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • TRANSPLANT PATIENTS: Adults greater than or equal to age 18, non-pregnant, non-lactating, attending Canadian Transplant Association meetings, BMI ≥ 25kg/m2, ≥1 year stable (not being treated for transplant rejection or infection) post-transplant, having access to a computer with email or a telephone at least one day per week and English speaking.
  • PATIENTS AT RISK FOR TYPE 2 DIABETES: Adults greater than or equal to age 18, non-pregnant, non-lactating, BMI ≥ 25kg/m2, not having progressed to type 2 diabetes, having access to a computer with email or a telephone at least one day per week and English speaking.

Exclusion Criteria:

  • TRANSPLANT PATIENTS: Patients with BMI <25 kg/m2, unwilling to undergo PNT, unable to provide consent, undergoing treatment for transplant rejection or infection, not English speaking, without access to a computer with email or a telephone at least one day per week and/or <1 year post-transplant, seeing another healthcare provider for weight loss advice outside of this study
  • PATIENTS AT RISK FOR TYPE 2 DIABETES: Patients with BMI <25 kg/m2, unwilling to undergo PNT, unable to provide consent, having been diagnosed with type 2 diabetes, not English speaking, without access to a computer with email or a telephone at least one day per week, seeing another healthcare provider for weight loss advice outside of this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03015012

Contacts
Contact: Janet Madill, PhD 519 432 8353 ext 28240 jmadill7@uwo.ca
Contact: Justine Horne, MSc 519 212 0917 jhorne5@uwo.ca

Locations
Canada, Ontario
East Elgin Family Health Team Recruiting
Aylmer, Ontario, Canada, N5H1K9
Contact: Justine Horne, MSc    519-773-3715 ext 136    jhorne@eefht.ca   
Brescia University College Recruiting
London, Ontario, Canada, N6G 1H2
Contact: Janet Madill, PhD    519 432 8353 ext 28240    jmadill7@uwo.ca   
Contact: Justine Horne, MSc    519 212 0917    jhorne5@uwo.ca   
Sponsors and Collaborators
Western University, Canada
Nutrigenomix Inc.
East Elgin Family Health Team
Canadian Transplant Association
Investigators
Principal Investigator: Janet Madill, PhD Brescia University College at Western University
  More Information

Publications:
Responsible Party: Western University, Canada
ClinicalTrials.gov Identifier: NCT03015012     History of Changes
Other Study ID Numbers: 108511
Study First Received: January 5, 2017
Last Updated: April 25, 2017
Individual Participant Data  
Plan to Share IPD: No
Plan Description: IPD will only be available to the current research team.

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Western University, Canada:
Nutrigenomics
Genetics
Overweight
Obesity
Transplantation
Nutrition
Dietetics
BMI
Body Composition

Additional relevant MeSH terms:
Obesity
Overweight
Overnutrition
Nutrition Disorders
Body Weight
Signs and Symptoms

ClinicalTrials.gov processed this record on May 24, 2017